Comparative Survival Rate, Ocular Quality of Life and Social Quality of Life in Patients with Malignant T3-T4 Orbito-Sinusal Tumors Treated with Exenteration vs. Conservative Procedures

Cherecheanu, Alina Popa; Stana, Daniela; Ungureanu, Emil; Ionescu, Diana N.; Cherecheanu, Matei Popa; Şerban, Dragoş; Dascălu, Ana Maria

doi:10.1016/j.sbspro.2013.04.311

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The symptoms of cSCC and the high morbidity associated with standard treatment for the disease can result in pain, scarring, disfigurement and anxiety, any of which can affect patients' overall health-related quality of life (HRQoL) [5,6]. Patients with cSCC may experience negative psychosocial and mental health effects as a result of treatments that alter their physical appearance or impede their ability to speak, swallow or see, particularly in those with advanced cSCC in the anatomic regions above the clavicle [6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629

Hughes

Mendoza²,

Basset-Séguin

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Pembrolizumab provided durable responses and acceptable safety in recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC) in the KEYNOTE-629 study. In this elderly, fragile population with disfiguring tumours, preservation of health-related quality of life (HRQoL) is critical. Here, we present pre-specified exploratory HRQoL anal-yses from the first interim analysis of KEYNOTE-629. Methods: Patients with R/M cSCC not amenable to surgery or radiation therapy received pembrolizumab 200 mg every 3 weeks for B 24 months. HRQoL end points included change from baseline to week 12 in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) global health status (GHS)/ QoL, functioning, symptom and European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) scores and change from baseline through week 48 in EORTC QLQ-C30 GHS/QoL and physical functioning scores. Improvement (C 10-point increase post-baseline with confirmation) was Results: Analyses included 99 patients for EORTC QLQ-C30 and 100 for EQ-5D-5L. Compliance was [ 80% at week 12. Mean scores were stable from baseline to week 12 for GHS/ QoL (4.95 points; 95% confidence interval, -1.00 to 10.90) and physical functioning (-3.38 points; 95% confidence interval, -8.80 to 2.04). EORTC-QLQ-C30 functioning, symptom, and EQ-5D-5L scores remained stable at week 12. Post-baseline scores were improved in 29.3% of patients for GHS/QoL, 17.2% for physical functioning, and in a numerically higher proportion of responders versus non-responders (GHS/QoL, 55.6% versus 16.1%; physical functioning, 36.1% versus 7.1%). Conclusions: In elderly patients with R/M cSCC, the clinical efficacy of pembrolizumab translates into a benefit validated by HRQoL preservation or improvement during treatment. Trial Registration: ClinicalTrials.gov identifier: NCT03284424.

show abstract

Section: Introductionmentioning

confidence: 99%

Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629

Hughes

Mendoza²,

Basset-Séguin

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

Survival benefit of exenteration in COVID-19-associated rhino-orbital mucormycosis

Raj,

Singh,

Sadhukhan

et al. 2023

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: There has been a sudden increase in the number of rhino-orbital mucormycosis cases, primarily affecting patients recovering from COVID-19 infection. The local health authorities have declared the current situation an epidemic. In this study, we assess the role of exenteration in preventing disease progression and improving survival in patients with rhino-orbital mucormycosis. Methods: The patients undergoing exenteration were grouped into the exenteration arm and those denying exenteration were grouped into the nonexenteration arm. The patients were followed at 1 month and 3 months. The 6-month survival data were collected telephonically. Continuous data were presented as Mean ± SD/Median (IQR) depending on the normality distribution of data, whereas the frequency with percentages was used to present the categorical variables. Kaplan–Meier survival curves were created to estimate the difference in survival of patients with exenteration in rhino-orbital mucormycosis versus those without exenteration. Results: A total of 14 patients were recruited for our study based on the inclusion and exclusion criteria. All the patients were qualified for exenteration; however, only eight patients underwent exenteration and six patients did not consent to exenteration. At the end of 3 months in the exenteration group, four (50%) patients died. Two patients died within a week of exenteration, whereas two patients died after 2 weeks of exenteration. The deaths in the first week were attributed to septic shock and the deaths happening beyond 2 weeks were attributed to severe meningitis. The Kaplan–Meier survival analysis showed the cumulative probability of being alive at 1 month in the exenteration arm to be 85%, and it decreased to 67% by 53 days and subsequently remained stable until the end of 3 months. Conclusion: The Kaplan–Meier survival analysis did not show a survival benefit of exenteration at 3 months and 6 months in COVID-associated rhino-orbital mucormycosis.

show abstract

Comparative Survival Rate, Ocular Quality of Life and Social Quality of Life in Patients with Malignant T3-T4 Orbito-Sinusal Tumors Treated with Exenteration vs. Conservative Procedures

Cited by 2 publications

References 7 publications

Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629

Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629

Survival benefit of exenteration in COVID-19-associated rhino-orbital mucormycosis

Contact Info

Product

Resources

About